The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Different Cycles of Capecitabine Usage in Esophageal Cancer Concurrent Chemoradiotherapy
Official Title:
Study ID: NCT02603159
Brief Summary: Definitive chemoradiotherapy with cisplatin with cisplatin plus 5-fluorouracil is the standard in Western countries in esophagus cancer.But in China because of its toxic reaction, most of patients stop the halfway.Because low toxicity, Capecitabine is widely used in the chemotherapy of esophageal cancer. The purpose of this experiment was to study the different cycle on capecitabine with chemotherapy for esophageal cancer chemoradiation effect.We are prepared to within 2 years study recruited 200 patients with esophageal cancer.The primary endpoint is overall survival and the secondary endpoints include progression-free survival, response rate,pathologic complete response rate and adverse events.
Detailed Description: We recruited the patients who were pathologically confirmed with esophageal squamous cell carcinoma from the Oct 2014. The the patients was divided into two groups. Group 1: Capecitabine + chemoradiation, radiation at the end of the stop using capecitabine. Group 2: Capecitabine + chemoradiation, at the end of the radiotherapy with capecitabine consolidating treatment for 5 weeks.
Minimum Age: 45 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
Name: Shegan Gao, Doctor
Affiliation: The First Affiliated Hospital of Henan University of Science and Technology
Role: STUDY_CHAIR
Name: Tanyou Shan, Master
Affiliation: The First Affiliated Hospital of Henan University of Science and Technology
Role: STUDY_DIRECTOR
Name: Xiaoshan Feng, Doctor
Affiliation: The First Affiliated Hospital of Henan University of Science and Technology
Role: STUDY_DIRECTOR
Name: Jiachun Sun, Doctor
Affiliation: The First Affiliated Hospital of Henan University of Science and Technology
Role: PRINCIPAL_INVESTIGATOR
Name: Xinshuai Wang, Doctor
Affiliation: The First Affiliated Hospital of Henan University of Science and Technology
Role: PRINCIPAL_INVESTIGATOR
Name: Guoqiang Kong, Master
Affiliation: The First Affiliated Hospital of Henan University of Science and Technology
Role: PRINCIPAL_INVESTIGATOR
Name: Xiaozhi Yuan, Master
Affiliation: The First Affiliated Hospital of Henan University of Science and Technology
Role: PRINCIPAL_INVESTIGATOR
Name: Ruinuo Jia, Master
Affiliation: The First Affiliated Hospital of Henan University of Science and Technology
Role: PRINCIPAL_INVESTIGATOR
Name: Dan Zhuo, Master
Affiliation: The First Affiliated Hospital of Henan University of Science and Technology
Role: PRINCIPAL_INVESTIGATOR
Name: Jing Ren, Master
Affiliation: The First Affiliated Hospital of Henan University of Science and Technology
Role: PRINCIPAL_INVESTIGATOR
Name: Ruina Yang, Master
Affiliation: The First Affiliated Hospital of Henan University of Science and Technology
Role: PRINCIPAL_INVESTIGATOR
Name: Yali Zhang, Master
Affiliation: The First Affiliated Hospital of Henan University of Science and Technology
Role: PRINCIPAL_INVESTIGATOR
Name: Yongxuan Liu, Master
Affiliation: The First Affiliated Hospital of Henan University of Science and Technology
Role: PRINCIPAL_INVESTIGATOR
Name: Wei Wang, Master
Affiliation: The First Affiliated Hospital of Henan University of Science and Technology
Role: PRINCIPAL_INVESTIGATOR
Name: Dan Wang, Master
Affiliation: The First Affiliated Hospital of Henan University of Science and Technology
Role: PRINCIPAL_INVESTIGATOR
Name: Weijiao Yin, Master
Affiliation: The First Affiliated Hospital of Henan University of Science and Technology
Role: PRINCIPAL_INVESTIGATOR
Name: Shiyuan Song, Master
Affiliation: The First Affiliated Hospital of Henan University of Science and Technology
Role: PRINCIPAL_INVESTIGATOR